Objective To investigate the expression and significance of CD58 in gliomas.Methods TCGA database was used to obtain the gene sequencing results and clinical information of glioma-related samples， and the expression of CD58 and its correlation with survival and prognosis were compared between the glioblastoma （GBM） group， low-grade glioma （LGG） group， and non-tumor brain tissue group （non-tumor group）. A prognostic model was established to analyze the correlation between CD58 expression and risk score and the difference in overall survival between CD58 high expression group and low expression group. A total of 40 clinical samples were divided into non-tumor brain tissue group （non-tumor group）， LGG group （grade I/Ⅱ gliomas）， and high-grade gliomas （HGG） group （grade Ⅲ/Ⅳ gliomas）， and immunohistochemistry was used to measure the expression of CD58， which was then compared between the three groups.Results The analysis of the difference in CD58 expression showed that the GBM group had the highest CD58 expression， followed by the LGG group and the non-tumor group （P <0.05）. Risk score was positively correlated with CD58 expression， and the higher the expression of CD58， the shorter the survival time of patients （P <0.05）. The multivariate Cox regression analysis showed that CD58 expression was an influencing factor for the prognosis of glioma， and the higher the expression of CD58， the greater the risk of death. Immunohistochemistry showed that CD58 positive reactants were located in cell membrane， and the HGG group had a significantly higher number of positive cells than the LGG group and the non-tumor group （P <0.05）， while there was no significant difference in the number of positive cases between the three groups.Conclusions The expression of CD58 in high-grade gliomas is higher than that in low-grade gliomas and non-tumor brain tissue. The difference in CD58 expression is associated with the survival of gliomas， and the high expression of CD58 is a risk factor for the prognosis of gliomas. Therefore， CD58 can be used as an index to judge the degree of malignancy and the prognosis of glioma.